APA (7th ed.) Citation

Rustin, G., Vergote, I., Micha, J., Duska, L., Reed, N., Bendell, J., . . . Garcia, A. (2017). A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. Gynecologic Oncology, 147(2), 276. https://doi.org/10.1016/j.ygyno.2017.08.026

Chicago Style (17th ed.) Citation

Rustin, G., et al. "A Multicenter, Open-label, Expanded Phase 2 Study to Evaluate the Safety and Efficacy of Etirinotecan Pegol, a Polymer Conjugate of Irinotecan, in Women with Recurrent Platinum-resistant or Refractory Ovarian Cancer." Gynecologic Oncology 147, no. 2 (2017): 276. https://doi.org/10.1016/j.ygyno.2017.08.026.

MLA (9th ed.) Citation

Rustin, G., et al. "A Multicenter, Open-label, Expanded Phase 2 Study to Evaluate the Safety and Efficacy of Etirinotecan Pegol, a Polymer Conjugate of Irinotecan, in Women with Recurrent Platinum-resistant or Refractory Ovarian Cancer." Gynecologic Oncology, vol. 147, no. 2, 2017, p. 276, https://doi.org/10.1016/j.ygyno.2017.08.026.